11 March 2009
Waiting Longer for Two Mutations, Part 3
Michael J. Behe
Dear Readers,
An interesting paper appeared several months ago in an issue of the journal Genetics, “Waiting for Two Mutations: With Applications to Regulatory Sequence Evolution and the Limits of Darwinian Evolution” (Durrett, R & Schmidt, D. 2008. Genetics 180: 1501-1509). This is the third of five posts that discusses it. Cited references will appear in the last post.
The third problem also concerns the biology of the system. I’m at a bit of a loss here, because the problem is not hard to see, and yet in their reply they stoutly deny the mistake. In fact, they confidently assert it is I who am mistaken. I had written in my letter, ‘‘… their model is incomplete on its own terms because it does not take into account the probability of one of the nine matching nucleotides in the region that is envisioned to become the new transcription-factor-binding site mutating to an incorrect nucleotide before the 10th mismatched codon mutates to the correct one.’’ They retort, “This conclusion is simply wrong since it assumes that there is only one individual in the population with the first mutation.” That’s incorrect. Let me explain the problem in more detail.
Consider a string of ten digits, either 0 or 1. We start with a string that has nine 1’s, and just one 0. We want to convert the single 0 to a 1 without switching any of the 1’s to a zero. Suppose that the switch rate for each digit is one per hundred copies of the string. That is, we copy the string repeatedly, and, if we focus on a particular digit, about every hundredth copy or so that digit has changed. Okay, now cover all of the numbers of the string except the 0, and let a random, automated procedure copy the string, with a digit-mutation rate of one in a hundred. After, say, 79 copies, we see that the visible 0 has just changed to a 1. Now we uncover the rest of the digits. What is the likelihood that one of them has changed in the meantime? Since all the digits have the same mutation rate, then there is a nine in ten chance that one of the other digits has already changed from a 1 to a 0, and our mutated string still does not match the target of all 1’s. In fact, only about one time out of ten will we uncover the string and find that no other digits have changed except the visible digit. Thus the effective mutation rate for transforming the string with nine matches out of ten to a string with ten matches out of ten will be only one tenth of the basic digit-mutation rate. If the string is a hundred long, the effective mutation rate will be one-hundredth the basic rate, and so on. (This is very similar to the problem of mutating a duplicate gene to a new selectable function before it suffers a degradative mutation, which has been investigated by Lynch and co-workers. (2))
So, despite their self-assured tone, in fact on this point Durrett and Schmidt are “simply wrong.” And, as I write in my letter, since the gene for the chloroquine resistance protein has on the order of a thousand nucleotides, rather than just the ten of Durrett and Schmidt’s postulated regulatory sequence, the effective rate for the second mutation is several orders of magnitude less than they thought. Thus with the, say, two orders of magnitude mistake here, the factor of 30 error for the initial mutation rate, and the four orders of magnitude for mistakenly using a neutral model instead of a deleterious model, Durrett and Schmidt’s calculation is a cumulative seven and a half orders of magnitude off. Since they had pointed out that their calculation was about five million-fold (about six and a half orders of magnitude) lower than the empirical result I cited, when their errors are corrected the calculation agrees pretty well with the empirical data.
10 March 2009
Waiting Longer for Two Mutations, Part 2
Michael J. Behe
9 March 2009
Waiting Longer for Two Mutations, Part 1
Michael J. Behe
25 February 2009
Hog’s tail or bacon? Jerry Coyne in The New Republic
Michael J. Behe
15 January 2009
Miller vs. Luskin, Part 2
Michael J. Behe
At the end of his first post squabbling with Discovery Institute’s Casey Luskin, Brown University Professor Kenneth Miller refers to some great new work by UC San Diego Professor and member of the National Academy of Science Russell Doolittle. Doolittle, of course, has worked on the blood clotting cascade for about fifty years! (I discussed some of his work in Chapter 4 of Darwin’s Black Box.) In a new paper Doolittle and co-workers analyze DNA sequence data from a primitive vertebrate, the lamprey, thinking that it might have a simpler clotting cascade than higher vertebrates. (1) It is difficult work, because the sequences of lamprey proteins — even ones that are indeed homologous to the proteins of other vertebrates — are significantly diverged from, say, mammalian proteins.
They argue that most of the core clotting cascade proteins are present, but two seem to be absent: lamprey has single proteins that act as Factor V/VIII (proaccelerin/anti-hemophilic factor) and Factor IX/X (Christmas factor/Stuart factor). The authors then infer that either gene or genome duplication led to separation of the factors. Although it’s interesting work, Doolittle’s conclusions are only suggestive (and the authors clearly say that the data are only suggestive). They found four copies of genes that are similar to Factors V/VIII, as well as to the non-clotting proteins ceruloplasmin and hephaestin (Figure 2 in their paper). They argue that only one is a real blood clotting factor and the other three aren’t, but the arguments are pretty tentative. The same for Factors IX/X. The authors identify two “Factor X” genes. Might one of those be acting as a Factor IX gene? At the conclusion of the paper the authors say they may try to support their arguments with biochemical experiments. I’m looking forward to reading the results of those.
Whether or not their conclusion is correct, however, as far as the argument for intelligent design is concerned the only relevant part of Doolittle’s paper is Figure 10, which purports to show the clotting pathway in lamprey vs. other vertebrates. (Intelligent design is wholly compatible with common descent — including descent by gene duplication/rearrangement. Rather, ID argues against the Darwinian claim that complex, functional molecular systems could be built by a random, unguided process.) Yet to get from one arrangement to the other one would take multiple steps, not just one: whole genome duplication, retargeting of Factor IX, retargeting of Factor VIII, and so on. (The problems are essentially the same, as I pointed out in an essay in 2000 entitled “In Defense of the Irreducibility of the Blood Clotting Cascade,” posted on the Discovery Institute website.) So even if the suggested events occurred, they were extremely unlikely to have occurred by a Darwinian mechanism of random mutation/natural selection (the authors make no argument for a Darwinian mechanism). Guided, yes. Random, no.
It’s pertinent to remember here the central point of The Edge of Evolution. We now have data in hand that show what Darwinian processes can accomplish, and it ain’t much. We no longer have to rely on speculative scenarios that overlook barriers and problems that nature would encounter. Random mutation/natural selection works great in folks’ imaginations, but it’s a bust in the real world.
12 January 2009
Miller vs. Luskin, Part 1
Michael J. Behe
Dear Readers,
Brown University Professor Kenneth Miller has gotten into a little tiff with Discovery Institute’s Casey Luskin over what I said/meant about the blood clotting cascade in Darwin’s Black Box. This is the first of two posts commenting on that.
In Chapter 4 of Darwin’s Black Box I first described the clotting cascade and then, in a section called “Similarities and Differences”, analyzed it in terms of irreducible complexity. Near the beginning of that part I had written, “Leaving aside the system before the fork in the pathway, where details are less well known, the blood clotting system fits the definition of irreducible complexity… The components of the system (beyond the fork in the pathway) are fibrinogen, prothrombin, Stuart factor, and proaccelerin.” Casey Luskin concludes that from that point on I was focusing my argument on the system beyond the fork in the pathway, containing those components I named. That is a reasonable conclusion because, well, because that’s what I said I was doing, and Mr. Luskin can comprehend the English language.
Apparently Prof. Miller can’t. He breathlessly reports that one page after I had qualified my argument I wrote “Since each step necessarily requires several parts, not only is the entire blood-clotting system irreducibly complex, but so is each step in the pathway” and Miller asserts that meant I had inexplicably switched back to considering the whole cascade, including the initial steps. It seems not to have occurred to Miller that that sentence should be read in the context of the previous page, so he focuses on the components before the fork, the better to construct a strawman to knock down. In fact, in that section containing the second quote (“Since each step…”) I was arguing about the difficulty of inserting a new step into the middle of a generic, pre-existing cascade (“One could imagine a blood clotting system that was somewhat simpler than the real one—where, say, Stuart factor, after activation by the rest of the cascade, directly cuts fibrinogen to form fibrin, bypassing thrombin”), and likened it to inserting a lock in a ship canal. It could be done if an intelligent agent were directing it, but it would be really difficult to do by chance/selection. All that seems to have passed Miller by.
In philosophy there is something called the “principle of charitable reading.” In a nutshell it means that one should construe an author’s argument in the best way possible, so that the argument is engaged in its strongest form. Unfortunately, in my experience Miller does the opposite — call it the “principle of malicious reading.” He ignores (or doesn’t comprehend) context, ignores (or doesn’t comprehend) the distinctions an author makes, and construes the argument in the worst way possible. (See my previous posts on July 11-12, 2007 about Miller’s tendentious review of The Edge of Evolution.)
Good salesmanship. Bad scholarship.
16 June 2008
Once More With Feeling
Michael J. Behe
6 June 2008
Multiple Mutations Needed for E. Coli
Michael J. Behe
9 May 2008
Malaria and Mutations
Michael J. Behe
Dear Readers,
An interesting paper appeared recently in the New England Journal of Medicine. (1) The workers there discovered some new mutations which confer some resistance to malaria on human blood cells in the lab. (Their usefulness in nature has not yet been nailed down.) The relevance to my analysis in The Edge of Evolution is that, like other mutations that help with malaria, these mutations, too, are ones which degrade the function of a normally very useful protein, called pyruvate kinase. As the workers note:
“[H]eterozygosity for partial or complete loss-of-function alleles . . . may have little negative effect on overall fitness (including transmission of mutant alleles), while providing a modest but significant protective effect against malaria. Although speculative, this situation would be similar to that proposed for hemoglobinopathies (sickle cell and both -thalassemia and -thalassemia) and G6PD deficiency. . .”
This conclusion supports several strong themes of The Edge of Evolution which reviewers have shied away from. First, that evenbeneficial mutations are very often degradative mutations. Second, it’s a lot faster to get a beneficial effect (if one is available to be had) by degrading a gene than by making specific changes in genes. The reason is that there are generally hundreds or thousands of ways to break a gene, but just a few to alter it beneficially without degrading it. And third, that random mutation plus natural selection is incoherent. That is, separate mutations are often scattered; they do not add up in a systematic way to give new, interacting molecular machinery.
Even in the professional literature, sickle cell disease is still called, along with other mutations related to malaria, “one of the best examples of natural selection acting on the human genome.” (2) So these are our best examples! Yet breaking pyruvate kinase or G6PD or globin genes in thalassemia does not add up to any new system. Then where do the elegant nanosystems found in the cell come from? Not from random mutation and natural selection, that’s for sure.
1. Ayi, K., et al. 2008. Pyruvate kinase deficiency and malaria. N. Engl. J. Med. 358:1805-1810.
2. Tishkoff, S.A., et al. 2001. Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistance. Science 293:455-462.


